Veradigm (MDRX) 10-Q 9 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 02, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		116,019,972
Entity File Number	001-35547
Entity Tax Identification Number	36-4392754
Entity Address, Address Line One	222 Merchandise Mart
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 82,782,000	$ 132,517,000
Restricted cash	1,305,000	1,308,000
Accounts receivable, net of allowance of $13,773 and $13,360 as of March 31, 2022 and December 31, 2021, respectively	170,497,000	171,622,000
Contract assets, net of allowance of [$576] as of March 31, 2022 and December 31, 2021	55,162,000	63,429,000
Prepaid expenses and other current assets	56,191,000	60,511,000
Assets held for sale	1,174,747,000	1,125,111,000
Total current assets	1,540,684,000	1,554,498,000
Fixed assets, net	9,299,000	9,819,000
Software development costs, net	78,334,000	74,688,000
Intangible assets, net	158,285,000	149,690,000
Goodwill	520,187,000	506,607,000
Deferred taxes, net	6,078,000	0
Contract assets - long-term, net of allowance of [$1,534] as of March 31, 2022 and December 31, 2021	19,198,000	28,174,000
Right-of-use assets - operating leases	16,776,000	18,324,000
Other assets	81,414,000	83,429,000
Total assets	2,430,255,000	2,425,229,000
Current liabilities:
Accounts payable	15,548,000	5,281,000
Accrued expenses	61,829,000	54,518,000
Accrued compensation and benefits	18,027,000	31,055,000
Deferred revenue	106,491,000	120,748,000
Current operating lease liabilities	5,972,000	6,133,000
Liabilities related to assets held for sale	438,988,000	380,253,000
Total current liabilities	646,855,000	597,988,000
Long-term debt	377,059,000	350,062,000
Deferred revenue	3,590,000	1,839,000
Deferred taxes, net	0	16,625,000
Long-term operating lease liabilities	15,241,000	16,754,000
Other liabilities	34,404,000	33,823,000
Total liabilities	1,077,149,000	1,017,091,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of March 31, 2022 and December 31, 2021; 277,696 and 114,792 shares issued and outstanding as of March 31, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively	2,776,000	2,766,000
Treasury stock: at cost, 162,904 and 160,591 shares as of March 31, 2022 and December 31, 2021, respectively	(1,371,484,000)	(1,321,805,000)
Additional paid-in capital	1,922,026,000	1,962,386,000
Retained earnings	802,890,000	767,556,000
Accumulated other comprehensive loss	(3,102,000)	(2,765,000)
Total stockholders’ equity	1,353,106,000	1,408,138,000
Total liabilities and stockholders’ equity	$ 2,430,255,000	$ 2,425,229,000

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 13,773	$ 13,360
Contract assets, allowance	576	576
Total contract assets, long-term	$ 1,534	$ 1,534
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	277,696,000	276,705,000
Common stock, shares outstanding	114,792,000	116,114,000
Treasury stock at cost, shares	162,904,000	160,591,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Revenue from contract with customers	$ 142,672	$ 133,652
Cost of revenue:
Total cost of revenue	69,191	70,735
Gross profit	73,481	62,917
Selling, general and administrative expenses	41,318	32,164
Research and development	23,420	20,660
Amortization of intangible and acquisition-related assets	2,171	2,364
Income from operations	6,572	7,729
Interest expense	(2,136)	(3,143)
Other income, net	12	798
Equity in net (loss) income of unconsolidated investments	(398)	22
Loss (income) from continuing operations before income taxes	4,050	5,406
Income tax benefit (provision)	14,421	(1,106)
Income from continuing operations, net of tax	18,471	4,300
(Loss) income from discontinued operations	(5,021)	5,820
Gain on sale of discontinued operations	0	647
Income tax effect on discontinued operations	9,407	(1,710)
Income from discontinued operations, net of tax	4,386	4,757
Net income	$ 22,857	$ 9,057
Basic
Continuing operations	$ 0.16	$ 0.03
Discontinued operations	0.04	0.03
Net income per share - Basic	0.20	0.06
Diluted
Continuing operations	0.14	0.03
Discontinued operations	0.03	0.03
Net income per share - Diluted	$ 0.17	$ 0.06
Provider [Member]
Revenue:
Revenue from contract with customers	$ 118,665	$ 111,170
Cost of revenue:
Total cost of revenue	57,017	58,866
Payer & Life Sciences [Member]
Revenue:
Revenue from contract with customers	24,007	22,482
Cost of revenue:
Total cost of revenue	$ 12,174	$ 11,869

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 22,857	$ 9,057
Other comprehensive income (loss):
Foreign currency translation adjustments	(150)	99
Change in fair value of derivatives qualifying as cash flow hedges	(251)	(681)
Other comprehensive (loss) income before income tax benefit	(401)	(582)
Income tax benefit related to items in other comprehensive income (loss)	64	176
Total other comprehensive income (loss)	(337)	(406)
Comprehensive income	$ 22,520	$ 8,651

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Cumulative Effect Period Of Adoption Adjustment [Member]Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Retained Earnings (Accumulated Deficit) [Member]	Retained Earnings (Accumulated Deficit) [Member]Cumulative Effect Period Of Adoption Adjustment [Member]Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	$ 1,902,776		$ 633,118		$ (1,838)
Stock-based compensation	8,701
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		683,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 6		(5,980)
Treasury Stock Shares Acquired			0
Purchase of treasury stock, Shares			0
Purchase of treasury stock			$ 0
Warrants issued				1,037
Net income (loss)						9,057
Foreign currency translation adjustments, net	99							99
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax								(505)
Ending Balance, Shares at Mar. 31, 2021		275,241,000	(134,616,000)
Ending Balance at Mar. 31, 2021	1,678,658	$ 2,751	$ (870,558)	1,906,534		642,175		(2,244)
Ending Balance (ASU 2020-06 [Member]) at Mar. 31, 2021					$ 0		$ 0
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	1,902,776		633,118		(1,838)
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	2,200,000
Ending Balance, Shares at Dec. 31, 2021	276,705,000	276,705,000	(160,591,000)
Ending Balance at Dec. 31, 2021	$ 1,408,138	$ 2,766	$ (1,321,805)	1,962,386		767,556		(2,765)
Stock-based compensation	$ 10,822
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	1,000,000	991,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 10		(13,301)
Treasury Stock Shares Acquired			(2,313,000)
Purchase of treasury stock, Shares			2,313,000
Purchase of treasury stock			$ (49,679)
Warrants issued				1,037
Net income (loss)						22,857
Accounting Standards Update [Extensible List]	Stock-based compensation
Foreign currency translation adjustments, net	$ (150)							(150)
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax								(187)
Ending Balance, Shares at Mar. 31, 2022	277,696,000	277,696,000	(162,904,000)
Ending Balance at Mar. 31, 2022	$ 1,353,106	$ 2,776	$ (1,371,484)	$ 1,922,026		$ 802,890		$ (3,102)
Ending Balance (ASU 2020-06 [Member]) at Mar. 31, 2022					$ (38,918)		$ 12,477

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)	Mar. 31, 2022	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument Interest Rate Stated Percentage	0.875%	0.875%	0.875%

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income	$ 22,857	$ 9,057
Less: Income from discontinued operations	4,386	4,757
Income from continuing operations	18,471	4,300
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,101	16,256
Non-cash lease expense, net	(3,223)	(1,760)
Stock-based compensation expense	6,324	2,841
Deferred taxes	(17,042)	4,657
Equity in net loss (income) of unconsolidated investments	398	(22)
Other loss, net	226	716
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	26,205	26,234
Prepaid expenses and other assets	5,431	(2,039)
Accounts payable	10,210	(2,949)
Accrued expenses	13,031	3,178
Accrued compensation and benefits	(13,291)	(13,727)
Deferred revenue	(28,352)	(23,958)
Other liabilities	2,022	1,443
Net cash provided by (used in) operating activities - continuing operations	34,511	15,170
Net cash used in operating activities - discontinued operations	34,750	(10,595)
Net cash provided by operating activities	69,261	4,575
Cash flows from investing activities:
Capital expenditures	(345)	(225)
Capitalized software	(9,600)	(8,148)
Cash paid for business acquisitions, net of cash acquired	(24,106)	0
Sale of businesses and other investments, net of cash divested, and distributions received	1,083	1,753
Purchases of equity securities, other investments and related intangible assets, net	0	(221)
Net cash used in investing activities - continuing operations	(32,968)	(6,841)
Net cash used in investing activities - discontinued operations	(11,231)	(12,148)
Net cash used in investing activities	(44,199)	(18,989)
Cash flows from financing activities:
Taxes paid related to net share settlement of equity awards	(13,275)	(4,723)
Credit facility payments	(25,000)	0
Credit facility borrowings, net of issuance costs	25,000	0
Repurchase of common stock	(49,679)	0
Intercompany to/from parent/subsidiaries	11,685	28,373
Payment of acquisition and other financing obligations	0	(1,542)
Net cash (used in) provided by financing activities - continuing operations	(51,269)	22,108
Net cash provided by (used in) financing activities - discontinued operations	(11,697)	(29,622)
Net cash used in financing activities	(62,966)	(7,514)
Effect of exchange rate changes on cash and cash equivalents	(11)	(27)
Net decrease in cash and cash equivalents	(37,915)	(21,955)
Cash, cash equivalents and restricted cash, beginning of period	190,520	537,465
Cash, cash equivalents and restricted cash, end of period	152,605	515,510
Less: Cash and cash equivalents and restricted cash included in current assets held for sale	(68,518)	(60,430)
Cash, cash equivalents and restricted cash, end of period, excluding current assets held for sale	$ 84,087	$ 455,080

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also requires the application of the if-converted method for calculating diluted earnings per share, whereas the treasury stock method is no longer permitted for convertible instruments. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition, which resulted in an increase in long-term debt of $ 26.4 million, a decrease in additional paid-in capital of $ 38.9 million and an increase to retained earnings of $ 12.5 million, as of January 1, 2022. Refer to Note 10, “Debt” for additional information. Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “ Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ” (“ASU 2021-08”) , which requires contract assets and contract liabilities (deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “ Revenue from Contracts with Customers” , as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, “ Business Combinations” . The new standard should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The standard is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the effects of the adoption of ASU 2021-08 on our consolidated financial statements. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	2. Revenue from Contracts with Customers Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. At March 31, 2022 and December 31, 2021, we had capitalized costs to obtain or fulfill a contract of $ 8.3 million and $ 8.1 million, respectively, in Prepaid and other current assets and $ 10.9 million and $ 11.9 million, respectively, in Other assets. During the three months ended March 31, 2022 and 2021, we recognized $ 2.9 million and $ 3.3 million, respectively, of amortization expense related to such capitalized costs. The amortization of these capitalized costs to obtain a contract are included in Selling, general and administrative expense within our consolidated statements of operations. The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivable, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue. The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below: (In thousands) Three Months Revenue related to deferred revenue balance at beginning of period $ 36,151 Revenue related to new performance obligations satisfied during the period 45,306 Revenue recognized under "right-to-invoice" expedient 61,114 Reimbursed travel expenses, shipping and other revenue 101 Total revenue $ 142,672 (In thousands) Three Months Revenue related to deferred revenue balance at beginning of period $ 29,401 Revenue related to new performance obligations satisfied during the period 47,263 Revenue recognized under "right-to-invoice" expedient 56,811 Reimbursed travel expenses, shipping and other revenue 177 Total revenue $ 133,652 The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total unsatisfied performance obligations equaled $ 1.0 billion as of March 31, 2022, of which we expect to recognize approximately 38 % over the next 12 months, and the remaining 62 % thereafter. Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment. We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount and uncertainty of our revenue and cash flows are affected by economic factors. The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segments. Refer to Note 16, “Business Segments”, for further information regarding the change to our reportable segments during the first quarter of 2022. Three Months Ended March 31, 2022 (In thousands) Veradigm Unallocated Amounts Total Provider $ 112,271 $ 6,394 $ 118,665 Payer & Life Sciences 24,007 0 24,007 Total revenue $ 136,278 $ 6,394 $ 142,672 Three Months Ended March 31, 2021 (In thousands) Veradigm Unallocated Amounts Total Provider $ 103,888 $ 7,282 $ 111,170 Payer & Life Sciences 22,482 0 22,482 Total revenue $ 126,370 $ 7,282 $ 133,652 Contract Assets – Estimate of Credit Losses We adopted Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ( “ ASU 2016-13”) on January 1, 2020 using the cumulative-effect adjustment transition method. The guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets and trade receivables. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. We segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment and business size. We also used each customer’s primary business unit in our pooling determination . This assessment provides information of the customer including size, segment and industry. The pools are aligned with management’s current review of financial performance. For the three months ended March 31, 2022, no adjustment to the pools was necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a 24-month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The analysis for the three months ended March 31, 2022 resulted in no change to the estimate of credit losses. Changes in the estimate of credit losses for contract assets are presented in the table below. Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 2,110 $ 2,110 Current period provision 0 0 Ending balance $ 2,110 $ 2,110 Less: Contract assets, short-term 576 576 Total contract assets, long-term $ 1,534 $ 1,534

Accounts Receivable

Accounts Receivable	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Accounts Receivable	3. Accounts Receivable Trade Accounts Receivable – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. Refer to Note 2, “Revenue from Contracts with Customers” for information regarding the adoption of ASU 2016-13. No adjustments were made to the pools or historical loss rate data for trade accounts receivable during the three months ended March 31, 2022. Changes in the estimate of credit losses for trade accounts receivable are presented in the table below. Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 13,360 $ 14,769 Current period provision 754 340 Write-offs ( 341 ) ( 894 ) Ending balance $ 13,773 $ 14,215

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Lessee Disclosure [Abstract]
Leases	4. Leases We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at the commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. We have elected the group of practical expedients under Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically consist of executory costs, and the practical expedient allows for executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities. Our operating leases mainly include office leases, and our finance leases included office and computer equipment leases. As of December 31, 2021, we no longer have finance leases. Our finance leases in 2021 were not significant. Our operating leases have remaining lease terms up to 5 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year . Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended March 31, 2022 2021 Operating lease cost (1) $ 1,690 $ 1,931 Less: Sublease income ( 33 ) ( 83 ) Total operating lease costs $ 1,657 $ 1,848 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations . Supplemental cash flow information for operating leases is as follows: (In thousands) Three Months Ended March 31, 2022 2021 Operating cash flows from operating leases $ 1,864 $ 1,506 The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) March 31, 2022 December 31, 2021 Right-of-use assets - operating leases $ 16,776 $ 18,324 Current operating lease liabilities $ 5,972 $ 6,133 Long-term operating lease liabilities $ 15,241 $ 16,754 Weighted average remaining lease term (in years) 4 5 Weighted average discount rate 3.3 % 3.4 % The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of March 31, 2022. March 31, 2022 (In thousands) Operating Leases Remainder of 2022 $ 4,945 2023 6,317 2024 3,602 2025 3,440 2026 2,835 Thereafter 1,581 Total lease liabilities 22,720 Less: Amount representing interest ( 1,507 ) Less: Short-term lease liabilities ( 5,972 ) Total long-term lease liabilities $ 15,241

Business Combinations and Dives

Business Combinations and Divestitures	3 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Business Combinations and Divestitures	5. Business Combinations and Divestitures Acquisitions On March 25, 2022 , we acquired Babel Health which engages in the business of designing, developing, selling and operating encounter data submission and reconciliation solutions. The base purchase price was $ 24.0 million, subject to adjustment for cash and net working capital balances, resulting in $ 24.5 million in cash paid ($ 24.1 million in net cash after accounting for the existing cash balance). The preliminary purchase price allocation has resulted in $ 12.4 million in intangibles, allocated between trade name, customer relationship and technology assets, and $ 13.6 million in goodwill, offset by a $ 1.3 million deferred tax liability, and the remaining net working capital deficit. The allocation of the purchase price is preliminary and subject to change. The primary areas of the purchase price that are not yet finalized are related to working capital, intangible assets and the residual goodwill. Accordingly, adjustments may be made to the values of assets and liabilities assumed as the valuation is finalized and additional information is obtained about the facts and circumstance that existed at the acquisition date. The management platform will provide managed health care plans with a tailored solution for the risk adjustment claims submission process. The business is included in our Veradigm business segment. Divestitures On March 2, 2022, we entered into a purchase agreement (the “Harris Purchase Agreement”) with Harris Dawn Holdings Inc. (“Harris”), a wholly-owned subsidiary of Constellation Software Inc., an Ontario corporation, to sell substantially all of the assets of our Hospitals and Large Physician Practices business, including the Sunrise and TouchWorks solutions (the “Hospitals and Large Physician Practices Business”) for $ 670.0 million in cash at closing and the opportunity to earn up to an additional $ 30.0 million based on the Hospitals and Large Physician Practices Business’s revenue through calendar year 2023. Certain assets relating to the Hospitals and Large Physician Practices Business will be excluded from the transaction and retained by the Company, as described in the Harris Purchase Agreement. In addition, Harris will assume certain liabilities related to the Hospitals and Large Physician Practices Business under the terms of the Harris Purchase Agreement. The transactions contemplated by the Harris Purchase Agreement are subject to customary closing conditions, including the applicable waiting period (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR”). The HSR waiting period expired as of April 15, 2022. Each party’s obligation to consummate the divestiture is also subject to certain additional conditions, including performance in all material respects by the other party of its obligations under the Harris Purchase Agreement. The Harris Purchase Agreement contains certain termination rights for both Harris and the Company, including if the closing has not occurred by September 2, 2022, or upon the Company intending to enter into a competing transaction (as described in the Harris Purchase Agreement) upon payment of a termination fee. As of March 31, 2022, the assets and liabilities related to the Harris Purchase Agreement were classified as held for sale on our consolidated balance sheet. The held for sale assets and liabilities are classified as current since, as of March 31, 2022, we expected to complete the sale within the next 12 months. The Hospitals and Large Physician Practices Business classified as held for sale was also classified in discontinued operations as the disposition represents a strategic shift that will have a major effect on our operations and financial results. Refer to Note 15, “Discontinued Operations” for additional information regarding the Hospitals and Large Physician Practices Business and the held for sale assets and liabilities presented on our consolidated balance sheet. On May 2, 2022, we completed the sale of the Hospitals and Large Physician Practices Business, which is further discussed in Note 18, “Subsequent Events”. On August 23, 2021, we completed the sale of substantially all of the assets of our 2bPrecise business to a third party for a non-controlling interest in the combined entity. We realized a pre-tax gain upon the sale of $ 8.4 million, which was included in the Gain on sale of businesses, net line in our consolidated statements of operations for the year ended December 31, 2021. The historical 2bPrecise business is presented in our “Unallocated Amounts” category. On December 31, 2020, we completed the sale of substantially all of the assets of our CarePort business to a subsidiary of WellSky Corp., a Delaware corporation (“WellSky”), pursuant to a purchase agreement (the “CarePort Purchase Agreement”). The total consideration for CarePort was $ 1.35 billion, which was subject to certain adjustments for liabilities assumed by WellSky and net working capital as described in the CarePort Purchase Agreement. We realized a pre-tax gain upon the sale of $ 933.9 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. For the year ended December 31, 2021, we recorded a $ 0.6 million gain that primarily related to net working capital adjustments in the Gain on sale of discontinued operations line in our consolidated statements of operations. The divestiture was treated as a discontinued operation as of December 31, 2020. Refer to Note 15, “Discontinued Operations” for additional information. On December 31, 2020, we repaid $ 161.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below). On October 15, 2020, we completed the sale of substantially all of the assets of our EPSi TM business (“EPSi”) to Strata Decision Technology LLC, an Illinois limited liability company (“Strata”), and Roper Technologies, Inc., a Delaware corporation, pursuant to a purchase agreement (the “EPSi Purchase Agreement”). The total consideration for EPSi was $ 365.0 million, which was subject to certain adjustments for liabilities assumed by Strata and net working capital as described in the EPSi Purchase Agreement. We realized a pre-tax gain upon the sale of $ 222.6 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. The divestiture was treated as a discontinued operation as of December 31, 2020 . Refer to Note 15, “Discontinued Operations” for additional information. On October 29, 2020, we repaid $ 19.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below).

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	6. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instrument reflects the fair value of contingent consideration related to a completed acquisition. The fair value is based on a discounted cash flow analysis reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, commercial risk or time value of money. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2022 December 31, 2021 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange Prepaid expenses $ 0 $ 100 $ 0 $ 100 $ 0 $ 352 $ 0 $ 352 Total assets $ 0 $ 100 $ 0 $ 100 $ 0 $ 352 $ 0 $ 352 Contingent consideration Accrued $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 19 $ 19 Total liabilities $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 19 $ 19 The changes in our Level 3 liability measured at fair value on a recurring basis at March 31, 2022 is summarized as follows: (In thousands) Contingent Consideration Balance at December 31, 2021 $ 19 Payments ( 19 ) Balance at March 31, 2022 $ 0 Long-term Investments The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at March 31, 2022 Cost March 31, 2022 December 31, 2021 Equity method investments (1) 4 $ 7,099 $ 11,862 $ 12,260 Cost with adjustments 7 47,114 48,791 49,293 Total long-term equity investments 11 $ 54,213 $ 60,653 $ 61,553 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of March 31, 2022, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments, primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions. Impairment of Long-term Investments Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. Based on our assessment, we determined no impairment charges were necessary for the three months ended March 31, 2022. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as described in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. Refer to Note 10, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	7. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three months ended March 31, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 31, 2022 and 2021. Three Months Ended March 31, (In thousands) 2022 2021 Cost of revenue: Provider $ 317 $ 276 Payer & Life Sciences ( 12 ) 57 Total cost of revenue 305 333 Selling, general and administrative expenses 5,489 2,553 Research and development 1,130 1,068 Total stock-based compensation expense $ 6,924 $ 3,954 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2022 and 2021. We granted stock-based awards as follows: Three Months Ended March 31, 2022 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 25 $ 19.86 25 $ 19.86 During the three months ended March 31, 2022 and the year ended December 31, 2021, 1.0 million and 2.2 million shares of common stock, respectively, were issued in connection with the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax, and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the three months ended March 31, 2022 and 2021 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2022 and 2021 were 628 thousand and 383 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On January 24, 2022, we announced that our Board of Directors approved a new stock purchase program (the “2022 Program”) under which we may repurchase up to $ 250 million of our common stock, with no termination date. The 2022 Program replaced a previous program approved by our Board of Directors in 2021 that was fully utilized. During the three months ended March 31, 2022, we repurchased 2.3 million shares of our common stock under the 2022 Program for a total of $ 49.7 million (after commissions). There were no repurchases during the three months ended March 31, 2021. The approximate dollar value of shares of our common stock that may yet be purchased under the 2022 Program was $ 200.4 million as of March 31, 2022. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	8. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of restricted stock unit awards and warrants calculated under the treasury stock method, as well as convertible notes calculated under the if-converted method. The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2022 2021 Basic earnings per Common Share: Income from continuing operations, net of tax $ 18,471 $ 4,300 Income from discontinued operations, net of tax 4,386 4,757 Net income $ 22,857 $ 9,057 Weighted-average common shares outstanding 115,862 140,191 Basic earnings from continuing operations per Common Share $ 0.16 $ 0.03 Basic earnings from discontinued operations per Common Share 0.04 0.03 Net earnings per Common Share $ 0.20 $ 0.06 Diluted earnings per Common Share: Income from continuing operations, net of tax $ 18,471 $ 4,300 Effect of assumed conversions: Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes 506 0 Income from continuing operations, net of tax after the effect of assumed conversions $ 18,977 $ 4,300 Income from discontinued operations, net of tax $ 4,386 $ 4,757 Weighted-average common shares outstanding 115,862 140,191 Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants 22,823 8,949 Weighted-average common shares outstanding assuming dilution 138,685 149,140 Diluted earnings from continuing operations per Common Share $ 0.14 $ 0.03 Diluted earnings from discontinued operations per Common Share 0.03 0.03 Net earnings per Common Share $ 0.17 $ 0.06 The following restricted stock unit awards, convertible notes and warrants are not included in the computation of diluted earnings per share as the effect of including such restricted stock unit awards, convertible notes and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2022 2021 Shares subject to anti-dilutive restricted stock unit awards, convertible notes and warrants excluded from calculation 0 5,360

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: March 31, 2022 December 31, 2021 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 254,385 $ ( 229,033 ) $ 25,352 $ 249,483 $ ( 227,408 ) $ 22,075 Customer contracts and relationships 404,934 ( 324,001 ) 80,933 397,445 ( 321,830 ) 75,615 Total $ 659,319 $ ( 553,034 ) $ 106,285 $ 646,928 $ ( 549,238 ) $ 97,690 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 520,187 506,607 Total $ 572,187 $ 558,607 Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2022 were as follows: (In thousands) Veradigm Unallocated Total Balance as of December 31, 2021 467,630 38,977 506,607 Additions 13,580 0 13,580 Balance as of March 31, 2022 $ 481,210 $ 38,977 $ 520,187 There were no accumulated impairment losses associated with goodwill as of March 31, 2022 and December 31, 2021.

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	10. Debt Debt outstanding, excluding lease obligations, consists of the following: March 31, 2022 December 31, 2021 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 207,911 $ 4,331 $ 203,580 $ 167,853 $ ( 9,057 ) $ 176,910 Senior Secured Credit Facility 175,000 1,521 173,479 175,000 1,848 173,152 Total debt $ 382,911 $ 5,852 $ 377,059 $ 342,853 $ ( 7,209 ) $ 350,062 (1) As of March 31, 2022, the principal balance is recognized in debt. As of December 31, 2021, the principal balance is $ 207,911 thousand; $ 167,853 thousand is recognized in debt and $ 40,058 thousand is recognized in additional paid-in capital. Interest expense consists of the following: Three Months Ended March 31, (In thousands) 2022 2021 Interest expense $ 1,506 $ 1,288 Amortization of discounts and debt issuance costs 630 1,855 Total interest expense $ 2,136 $ 3,143 Interest expense related to the 0.875 % Convertible Senior Notes included in the table above consists of the following: Three Months Ended March 31, (In thousands) 2022 2021 Coupon interest $ 455 $ 455 Amortization of discounts and debt issuance costs 228 1,459 Total interest expense related to the convertible notes $ 683 $ 1,914 Allscripts Senior Secured Credit Facility On February 15, 2018, Allscripts and Allscripts Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $ 400 million senior secured term loan (the “Term Loan”) and a $ 900 million senior secured revolving facility (the “Revolving Facility”), each with a five-year term. We repaid the Term Loan in full on December 31, 2020. A total of up to $ 50 million of the Revolving Facility is available for the issuance of letters of credit, up to $ 10 million of the Revolving Facility is available for swingline loans, and up to $ 100 million of the Revolving Facility could be borrowed under certain foreign currencies. As of March 31, 2022, $ 175.0 million under the Revolving Facility and $ 1.0 million in letters of credit were outstanding under the Second Amended Credit Agreement. As of March 31, 2022, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 1.50 %, which totaled 1.96 %. We were in compliance with all covenants under the Second Amended Credit Agreement as of March 31, 2022. On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of our Second Amended Credit Agreement. The First Amendment provided the financial flexibility to settle the U.S. Department of Justice’s investigations as discussed in Note 14, “Contingencies”, while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. On July 20, 2020, we entered into a Second Amendment to the Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $ 1.4 million, of which a majority was capitalized. As of March 31, 2022, we had $ 724.0 million available borrowing capacity, net of outstanding letters of credit, under the Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings or if we are unable to maintain compliance with applicable covenants. On April 29, 2022, Allscripts and Allscripts Healthcare LLC entered into a Third Amended and Restated Credit Agreement (the “Third Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent and other lenders party thereto, amending and restating the Second Amended Credit Agreement, which is further discussed in Note 18, “Subsequent Events”. 0.875% Convertible Senior Notes The issuance in December 2019 of the combined $ 218.0 million aggregate principal amount of the 0.875 % Convertible Senior Notes resulted in $ 0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes, including any discounts and issuance costs, by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The semi-annual interest rate of 1.95 % was used to compute the initial fair value of the liability component, which totaled $ 177.9 million at the time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $ 40.1 million at the time of issuance before deducting any paid capped call fees. The equity component of $40.1 million, the $ 17.2 million in paid capped call fees and an allocation of $ 1.1 million in combined discounts and issuance costs were recorded in Additional paid-in capital within the consolidated balance sheets in December 2019. These were recorded as a discount and are to be accreted into interest expense through January 1, 2027 using the interest method. In June 2020, we paid $ 7.7 million to repurchase $ 10.1 million of the aggregate principal amount of the 0.875 % Convertible Senior Notes, which resulted in a $ 0.5 million gain. In connection with the repurchase, the capped call transaction was partially terminated, and we received $ 0.3 million, which resulted in a recognition of $ 0.8 million in equity to offset the capped call fees and a $ 0.5 million loss. On January 1, 2022, we adopted ASU 2020-06 using the modified retrospective transition method. The guidance simplifies the accounting for convertible instruments by removing major separation models required under GAAP. The guidance also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions. As a result of the adoption of ASU 2020-06, the liability and equity components of the 0.875% Convertible Senior Notes are to be presented as a single liability as of January 1, 2022. Therefore, as of January 1, 2022, we decreased Additional paid-in capital by $ 38.9 million, which represented the $ 40.1 million equity component, offset by the $ 1.1 million in combined discounts and issuance costs. We increased Retained earnings by $ 12.5 million to reverse the accretion of interest expense related to the equity component that was recorded from December 2019 through December 2021. We also increased Long-term debt by $ 26.4 million, which represents the difference between the reduction to Additional paid-in capital and the increase in Retained earnings. The capped call fees remain in Additional paid-in capital within our consolidated balance sheet. The 0.875 % Convertible Senior Notes became convertible at the option of the holders during the first quarter of 2022. However, as of March 31, 2022, none of the 0.875 % Convertible Senior Notes have been converted. The remaining principal amount of the 0.875 % Convertible Senior Notes at March 31, 2022 totaled $ 207.9 million. The carrying value of the capped call fees at March 31, 2022 was $ 16.4 million. Future Debt Payments The following table summarizes future debt principal payment obligations as of March 31, 2022: (In thousands) Total Remainder 2023 2024 2025 2026 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Revolving Facility (2) 175,000 0 175,000 0 0 0 0 Total debt $ 382,911 $ 0 $ 175,000 $ 0 $ 0 $ 0 $ 207,911 (1) Amount represents the face value of the 0.875 % Convertible Senior Notes. (2) Assumes no additional borrowings after March 31, 2022, payment of any required periodic installments of principal when due and that all drawn amounts are repaid upon maturity. On May 2, 2022, this amount was repaid with proceeds from the sale of the Hospitals and Large Physician Practices Business.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, “ Income Taxes” (“ASC 740”). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company’s ability to use these losses in the future. The effective tax rates were as follows: Three Months Ended March 31, (In thousands, except effective tax rate) 2022 2021 Income from continuing operations before income taxes $ 4,050 $ 5,406 Income tax benefit (provision) $ 14,421 $ ( 1,106 ) Effective tax rate NM 20.5 % NM - We define “NM” as not meaningful for percentages greater than 200%. Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items including a windfall benefit of $ 5.1 million for the three months ended March 31, 2022 and a windfall benefit of $ 1.0 million for the three months ended March 31, 2021. Our effective tax rates for the three months ended March 31, 2022, compared with the prior year comparable period, differ primarily due to the release of valuation allowance of $ 11.2 million in the three months ended March 31, 2022. In addition, the permanent items, credits and the impact of foreign earnings had more impact on the pre-tax income of $ 4.1 million in the three months ended March 31, 2022, compared to the impact of these items on a pre-tax income of $ 5.4 million for the three months ended March 31, 2021. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the three months ended March 31, 2022, we released valuation allowances of $ 11.2 million related to U.S. deferred tax assets. Our unrecognized income tax benefits were $ 30.5 million and $ 30.3 million as of March 31, 2022 and December 31, 2021, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law. Our Harris Purchase Agreement to sell substantially all of the assets of the Hospitals and Large Physician Practices Business includes the majority of our foreign subsidiaries. The assets and liabilities of these foreign subsidiaries have been classified as held for sale on our consolidated balance sheet. As such, the company no longer considers the undistributed earnings of these foreign subsidiaries to be indefinitely invested. Therefore, in the three months ended March 31, 2022, we have recorded a deferred tax asset of $ 7.0 million. The tax benefit of recording this deferred tax asset has been included in discontinued operations.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2022
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	12. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2022 Asset Derivatives (In thousands) Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 100 Total derivatives $ 100 December 31, 2021 Asset Derivatives (In thousands) Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 352 Total derivatives $ 352 Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of March 31, 2022, there were nine forward contracts outstanding that when entered into were staggered to mature monthly starting in April 2022 and ending in December 2022 . In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2022. As of March 31, 2022, the notional amount for each of the outstanding forward contracts ranged from 50.0 to 250.0 million INR, or the equivalent of $ 0.7 million to $ 3.3 million, based on the exchange rate between the United States dollar and the INR in effect as of March 31, 2022. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. As of March 31, 2022, we estimate that $ 0.1 million of net unrealized derivative gains included in accumulated other comprehensive income (loss) (“AOCI”) will be reclassified into income within the next 12 months . The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss): Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Location of Gain (Loss) Reclassified Three Months Foreign exchange contracts $ ( 148 ) Cost of Revenue $ 37 Selling, general and 24 Research and development $ 43 Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Location of Gain (Loss) Reclassified Three Months Foreign exchange contracts $ 175 Cost of Revenue $ 321 Selling, general and 184 Research and development $ 351

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Loss	13. Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2021 (1) $ ( 3,026 ) $ 261 $ ( 2,765 ) Other comprehensive (loss) income before ( 150 ) ( 110 ) ( 260 ) Net losses (gains) reclassified from accumulated 0 ( 77 ) ( 77 ) Net other comprehensive income (loss) ( 150 ) ( 187 ) ( 337 ) Balance as of March 31, 2022 (2) $ ( 3,176 ) $ 74 $ ( 3,102 ) (1) Net of taxes of $91 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $25 thousand for unrealized net gains on foreign exchange contract derivatives. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2020 (1) $ ( 2,957 ) $ 1,119 $ ( 1,838 ) Other comprehensive income (loss) before 99 130 229 Net (gains) losses reclassified from accumulated 0 ( 635 ) ( 635 ) Net other comprehensive income (loss) 99 ( 505 ) ( 406 ) Balance as of March 31, 2021 (2) $ ( 2,858 ) $ 614 $ ( 2,244 ) (1) Net of taxes of $ 390 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $ 214 thousand for unrealized net gains on foreign exchange contract derivatives. Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2022 2021 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ ( 150 ) $ 0 $ ( 150 ) $ 99 $ 0 $ 99 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period ( 148 ) 38 ( 110 ) 175 ( 45 ) 130 Net (gains) losses reclassified into income ( 103 ) 26 ( 77 ) ( 856 ) 221 ( 635 ) Net change in unrealized gains (losses) on foreign exchange contracts ( 251 ) 64 ( 187 ) ( 681 ) 176 ( 505 ) Other comprehensive (loss) income $ ( 401 ) $ 64 $ ( 337 ) $ ( 582 ) $ 176 $ ( 406 )

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Contingencies	14. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York related to the Horizon Clinicals software. In August 2018, McKesson received an additional CID (together with the May 2017 CID, the “McKesson CIDs”), related to the Paragon software. The McKesson CIDs request documents and information related to the certification McKesson obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. McKesson has agreed, with respect to the McKesson CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. In October 2021, Allscripts received a CID seeking information about its acquisition of the EIS Business from McKesson and the Horizon Clinicals software. McKesson has agreed to assume defense of this CID. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into a deferred prosecution agreement (the “Deferred Prosecution Agreement”) and various civil settlement agreements, including with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (collectively, the “Settlement Agreements”) resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. The Settlement Agreements required Practice Fusion to, among other things, pay a criminal fine of $ 25.3 million, a forfeiture payment of $ 959,700 and a civil settlement of $ 118.6 million, which includes $ 5.2 million designated for the state Medicaid program expenditures, all of which, as of December 31, 2020, were paid in full. The Deferred Prosecution Agreement required Practice Fusion to retain an “Oversight Organization” to oversee the Practice Fusion’s implementation of certain compliance measures and ongoing compliance efforts. On August 17, 2021, Practice Fusion’s initial Oversight Organization resigned, and on August 25, 2021, Practice Fusion received a notice from the U.S. Attorney’s Office for the District of Vermont stating Practice Fusion was in breach of the Deferred Prosecution Agreement due to such resignation. On September 17, 2021, Practice Fusion engaged a new Oversight Organization. On March 18, 2022, Practice Fusion reached a settlement with the U.S. Attorney’s Office concerning this claim, pursuant to which Practice Fusion agreed to pay $ 200,000 to the United States and extend the Deferred Prosecution Agreement by 11 weeks; Practice Fusion did not admit liability for any breach of the Deferred Prosecution Agreement. The settlement of $ 200,000 was paid by Practice Fusion on April 5, 2022.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2022
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	15. Discontinued Operations Hospitals and Large Physician Practices Discontinued Operation On March 2, 2022, we entered into the Harris Purchase Agreement to sell substantially all of the assets of the Hospitals and Large Physician Practices Business. The Hospitals and Large Physician Practices Business sale represents a strategic shift that will have a major effect on our operations and financial results. Therefore, as of March 31, 2022, we reported the Hospitals and Large Physician Practices Business as discontinued operations. On May 2, 2022, we completed the sale of the Hospitals and Large Physician Practices Business, which is further discussed in Note 18, “Subsequent Events.” The following table summarizes the major classes of assets and liabilities of the Hospitals and Large Physician Practices Business as reported on the consolidated balance sheets as of March 31, 2022 and December 31, 2021: (In thousands) March 31, 2022 December 31, 2021 Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations: Cash and cash equivalents $ 67,671 $ 55,834 Restricted cash 847 861 Accounts receivable, net of allowance of $ 18,045 and $ 16,584 as of March 31, 2022 and December 31, 2021, respectively 200,407 155,447 Contract assets, net of allowance of $ 492 as of March 31, 2022 and December 31, 2021 68,786 61,382 Prepaid expenses and other current assets 63,310 58,431 Total current assets 401,021 331,955 Fixed assets, net 33,686 38,083 Software development costs, net 91,810 97,416 Intangible assets, net 77,997 86,240 Goodwill 467,725 467,871 Deferred taxes, net 8,393 6,607 Contract assets - long-term, net of allowance of $ 739 as of March 31, 2022 and December 31, 2021 31,934 28,623 Right-of-use assets - operating leases 48,089 50,585 Other assets 14,092 17,731 Total assets (1) $ 1,174,747 $ 1,125,111 Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations: Accounts payable $ 21,708 $ 11,555 Accrued expenses 45,852 38,007 Accrued compensation and benefits 37,506 61,167 Deferred revenue 274,541 205,152 Current operating lease liabilities 13,613 13,466 Total current liabilities 393,220 329,347 Deferred revenue long-term 475 2,568 Long-term operating lease liabilities 44,952 48,068 Other liabilities 341 270 Total liabilities (1) $ 438,988 $ 380,253 (1) The total assets and total liabilities in the above table for the three months ended March 31, 2022 and for the year ended December 31, 2021, are presented in the balance sheet as of March 31, 2022 as Assets held for sale and Liabilities related to assets held for sale. The following table summarizes the major income and expense line items of the Hospitals and Large Physician Practices Business as reported in the consolidated statements of operations for the three months ended March 31, 2022 and 2021. Three Months Ended March 31, (In thousands) 2022 2021 Major income and expense line items related to Hospitals and Large Physician Practices: Revenue: Provider $ 214,230 $ 234,700 Total revenue 214,230 234,700 Cost of revenue: Provider 143,692 147,572 Total cost of revenue 143,692 147,572 Gross profit 70,538 87,128 Selling, general and administrative expenses 48,749 49,545 Research and development 23,856 28,513 Amortization of intangible assets 3,450 3,460 (Loss) income from discontinued operations for Hospitals and Large Physician Practices ( 5,517 ) 5,610 Other income, net 496 239 (Loss) income from discontinued operations for Hospitals and Large Physician Practices before income taxes ( 5,021 ) 5,849 Income tax benefit (provision) 9,407 ( 1,556 ) Income from discontinued operations, net of tax for Hospitals and Large Physician Practices $ 4,386 $ 4,293 EPSi and CarePort Discontinued Operation During 2020, we implemented a strategic initiative to sell two of our businesses, EPSi and CarePort. Since both businesses were part of the same strategic initiative and were sold within the same period, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. As of December 31, 2020, these businesses were reported together as discontinued operations. On October 15, 2020, we completed the sale of our EPSi business. Prior to the sale, EPSi was part of the “Unallocated Amounts” category as it did not meet the requirements to be a reportable segment nor the criteria to be aggregated into our two reportable segments. On its own, the divestiture of the EPSi business did not represent a strategic shift that had a major effect on our operations and financial results. However, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. Therefore, EPSi was treated as a discontinued operation. On December 31, 2020, we completed the sale of our CarePort business. Prior to the sale, CarePort was part of the former Data, Analytics and Care Coordination reportable segment. On its own, the divestiture of the CarePort business represented a strategic shift that had a major effect on our operations and financial results. The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statements of operations for the three months ended March 31, 2021. The activity during the three months ended March 31, 2021 relates to certain adjustments made in connection with the sale of EPSi and CarePort, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations. Three Months Ended (In thousands) March 31, 2021 Major income and expense line items related to EPSi and CarePort: Revenue: Provider $ ( 368 ) Total revenue ( 368 ) Cost of revenue: Provider ( 364 ) Total cost of revenue ( 364 ) Gross loss ( 4 ) Selling, general and administrative expenses 65 Research and development ( 40 ) Loss from discontinued operations for EPSi and CarePort ( 29 ) Gain on sale of discontinued operations 647 Income from discontinued operations for EPSi and CarePort before income taxes 618 Income tax provision ( 154 ) Income from discontinued operations, net of tax for EPSi and CarePort $ 464

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Business Segments	16. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services, such as outsourcing, private cloud hosting and revenue cycle management. As of January 1, 2022, we had three operating segments: (i) Hospitals and Large Physician Practices, (ii) Veradigm and (iii) Certain Products (as defined below). The Hospitals and Large Physician Practices and Veradigm operating segments were equivalent to the two reportable segments described below. The Hospitals and Large Physician Practices segment derived its revenue from the sale of integrated clinical and financial management solutions, which primarily included EHR-related software, related installation, support and maintenance, outsourcing and private cloud hosting. The Veradigm segment derived its revenue from payer and life sciences solutions, which are mainly targeted at payers, life sciences companies and other key healthcare stakeholders. Additionally, revenue was derived from software applications for patient engagement and the sale of EHR software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions. These solutions enabled clients to transition, analyze and coordinate care and improve the quality, efficiency and value of healthcare delivery across the entire care community. The “Unallocated Amounts” category consisted of the 2bPrecise business, certain products that were shifted from the previous Core Clinical and Financial Solutions reportable segment due to the organizational changes (“Certain Products”), transfer pricing revenues and certain corporate-related expenses. The amounts included in the “Unallocated Amounts” category for 2bPrecise and Certain Products did not meet the requirements to be reportable segments nor the criteria to be aggregated into the two reportable segments. On March 2, 2022, we entered into the Harris Purchase Agreement to sell substantially all of the assets of our Hospitals and Large Physician Practices Business. As of March 31, 2022, the assets and liabilities related to the Harris Purchase Agreement were classified as held for sale on our consolidated balance sheet. The held for sale assets and liabilities are classified as current since, as of March 31, 2022, we expected to complete the sale within the next 12 months. The Hospitals and Large Physician Practices Business classified as held for sale was classified in discontinued operations as the disposition represents a strategic shift that will have a major effect on our operations and financial results. As a result of the transaction, we have realigned our reporting structure. As of March 31, 2022, we have two operating segments: (i) Veradigm and (ii) Certain Products. The Veradigm operating segment is the equivalent to our one reportable segment. The prior period segment disclosures below have been revised to conform to the current period presentation. Our chief operating decision maker uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment. Three Months Ended March 31, (In thousands) 2022 2021 Revenue: Veradigm $ 136,278 $ 126,370 Unallocated Amounts 6,394 7,282 Total revenue $ 142,672 $ 133,652 Gross profit: Veradigm $ 69,195 $ 58,623 Unallocated Amounts 4,286 4,294 Total gross profit $ 73,481 $ 62,917 Income (loss) from operations: Veradigm $ 18,115 $ 11,494 Unallocated Amounts ( 11,543 ) ( 3,765 ) Total income (loss) from operations $ 6,572 $ 7,729

Supplemental Disclosures

Supplemental Disclosures	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	17. Supplemental Disclosures Supplemental Consolidated Statements of Cash Flows Information The majority of the restricted cash balance as of March 31, 2022 and 2021 represents lease deposits. March 31, (In thousands) 2022 2021 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 82,782 $ 453,772 Restricted cash 1,305 1,308 Total cash, cash equivalents and restricted cash $ 84,087 $ 455,080

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events On April 29, 2022, Allscripts and Allscripts Healthcare LLC entered into the Third Amended Credit Agreement, with JPMorgan Chase Bank, N.A., as administrative agent and other lenders party thereto, amending and restating the Second Amended Credit Agreement. The Third Amended Credit Agreement provides for a $ 700.0 million New Revolving Facility. A total of up to $ 50.0 million of the New Revolving Facility is available for the issuance of letters of credit, up to $ 25.0 million of the New Revolving Facility is available for swingline loans, and up to $ 100.0 million of the New Revolving Facility could be borrowed under certain foreign currencies. Proceeds from the borrowings under the Third Amended Credit Agreement were used for the refinancing of loans under the Second Amended Credit Agreement. On May 2, 2022, A llscripts, Allscripts Healthcare LLC, Allscripts Software, LLC, a Delaware limited liability company (“Allscripts Software”), PF2 EIS LLC, a Delaware limited liability company (“PF2”), Allscripts IHC, LLC, a Delaware limited liability company (“Allscripts IHC”), and Allscripts Healthcare US, LP, a Delaware limited partnership (together with Allscripts Healthcare LLC, Allscripts Software, PF2 and Allscripts IHC, the “Sellers”), completed the previously-announced divestiture of the net assets of the Sellers’ Hospitals and Large Physician Practices Business to Altera Digital Health Inc. (formerly known as Harris Dawn Holdings Inc.), a Delaware corporation (“Buyer”), a wholly-owned subsidiary of Constellation Software Inc., an Ontario corporation, pursuant to the Harris Purchase Agreement, dated March 2, 2022 (the “HLPP Divestiture”). At the closing of the HLPP Divestiture, Buyer acquired substantially all of the assets of the Business for $ 670.0 million in cash paid at closing and the opportunity to earn up to an additional $ 30.0 million based on the Hospitals and Large Physician Practices Business’s revenue through calendar year 2023. Certain assets of the Sellers relating to the Business were excluded from the transaction and retained by the Sellers. In addition, Buyer assumed certain liabilities related to the Business under the terms of the Purchase Agreement.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2022 and 2021 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also requires the application of the if-converted method for calculating diluted earnings per share, whereas the treasury stock method is no longer permitted for convertible instruments. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition, which resulted in an increase in long-term debt of $ 26.4 million, a decrease in additional paid-in capital of $ 38.9 million and an increase to retained earnings of $ 12.5 million, as of January 1, 2022. Refer to Note 10, “Debt” for additional information.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “ Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ” (“ASU 2021-08”) , which requires contract assets and contract liabilities (deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “ Revenue from Contracts with Customers” , as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, “ Business Combinations” . The new standard should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The standard is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the effects of the adoption of ASU 2021-08 on our consolidated financial statements. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2022
Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients	The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below: (In thousands) Three Months Revenue related to deferred revenue balance at beginning of period $ 36,151 Revenue related to new performance obligations satisfied during the period 45,306 Revenue recognized under "right-to-invoice" expedient 61,114 Reimbursed travel expenses, shipping and other revenue 101 Total revenue $ 142,672 (In thousands) Three Months Revenue related to deferred revenue balance at beginning of period $ 29,401 Revenue related to new performance obligations satisfied during the period 47,263 Revenue recognized under "right-to-invoice" expedient 56,811 Reimbursed travel expenses, shipping and other revenue 177 Total revenue $ 133,652
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segments. Refer to Note 16, “Business Segments”, for further information regarding the change to our reportable segments during the first quarter of 2022.
Summary of Changes in Estimate of Credit Losses for Contract Assets	Changes in the estimate of credit losses for contract assets are presented in the table below. Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 2,110 $ 2,110 Current period provision 0 0 Ending balance $ 2,110 $ 2,110 Less: Contract assets, short-term 576 576 Total contract assets, long-term $ 1,534 $ 1,534
Revenue by Segment [Member]
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	Three Months Ended March 31, 2022 (In thousands) Veradigm Unallocated Amounts Total Provider $ 112,271 $ 6,394 $ 118,665 Payer & Life Sciences 24,007 0 24,007 Total revenue $ 136,278 $ 6,394 $ 142,672 Three Months Ended March 31, 2021 (In thousands) Veradigm Unallocated Amounts Total Provider $ 103,888 $ 7,282 $ 111,170 Payer & Life Sciences 22,482 0 22,482 Total revenue $ 126,370 $ 7,282 $ 133,652

Accounts Receivable (Tables)

Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2022
Trade Accounts Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable	Changes in the estimate of credit losses for trade accounts receivable are presented in the table below. Three Months Ended March 31, (In thousands) 2022 2021 Beginning balance $ 13,360 $ 14,769 Current period provision 754 340 Write-offs ( 341 ) ( 894 ) Ending balance $ 13,773 $ 14,215

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Lessee Disclosure [Abstract]
Summary of Operating Costs Associated with Leased Assets	Operating costs associated with leased assets are as follows: (In thousands) Three Months Ended March 31, 2022 2021 Operating lease cost (1) $ 1,690 $ 1,931 Less: Sublease income ( 33 ) ( 83 ) Total operating lease costs $ 1,657 $ 1,848 (1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations .
Supplemental Cash Flow Information for Operating Leases	Supplemental cash flow information for operating leases is as follows: (In thousands) Three Months Ended March 31, 2022 2021 Operating cash flows from operating leases $ 1,864 $ 1,506
Summary of Balance Sheet Location and Balances for Operating Leases	The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) March 31, 2022 December 31, 2021 Right-of-use assets - operating leases $ 16,776 $ 18,324 Current operating lease liabilities $ 5,972 $ 6,133 Long-term operating lease liabilities $ 15,241 $ 16,754 Weighted average remaining lease term (in years) 4 5 Weighted average discount rate 3.3 % 3.4 %
Summary of Future Maturities of Lease and Non-Lease Components	The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of March 31, 2022. March 31, 2022 (In thousands) Operating Leases Remainder of 2022 $ 4,945 2023 6,317 2024 3,602 2025 3,440 2026 2,835 Thereafter 1,581 Total lease liabilities 22,720 Less: Amount representing interest ( 1,507 ) Less: Short-term lease liabilities ( 5,972 ) Total long-term lease liabilities $ 15,241

Fair Value Measurements and L_2

Fair Value Measurements and Long-term Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
Summary of Changes in Liability Measured at Fair Value on Recurring Basis	The changes in our Level 3 liability measured at fair value on a recurring basis at March 31, 2022 is summarized as follows: (In thousands) Contingent Consideration Balance at December 31, 2021 $ 19 Payments ( 19 ) Balance at March 31, 2022 $ 0
Long-Term Equity and Cost Method Investments [Member]
Summary of Long-term Equity Investments Included in Other Assets	The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at March 31, 2022 Cost March 31, 2022 December 31, 2021 Equity method investments (1) 4 $ 7,099 $ 11,862 $ 12,260 Cost with adjustments 7 47,114 48,791 49,293 Total long-term equity investments 11 $ 54,213 $ 60,653 $ 61,553 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Share-Based Compensation Expense	Stock-based compensation expense recognized during the three months ended March 31, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 31, 2022 and 2021. Three Months Ended March 31, (In thousands) 2022 2021 Cost of revenue: Provider $ 317 $ 276 Payer & Life Sciences ( 12 ) 57 Total cost of revenue 305 333 Selling, general and administrative expenses 5,489 2,553 Research and development 1,130 1,068 Total stock-based compensation expense $ 6,924 $ 3,954
Share-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended March 31, 2022 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 25 $ 19.86 25 $ 19.86

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2022 2021 Basic earnings per Common Share: Income from continuing operations, net of tax $ 18,471 $ 4,300 Income from discontinued operations, net of tax 4,386 4,757 Net income $ 22,857 $ 9,057 Weighted-average common shares outstanding 115,862 140,191 Basic earnings from continuing operations per Common Share $ 0.16 $ 0.03 Basic earnings from discontinued operations per Common Share 0.04 0.03 Net earnings per Common Share $ 0.20 $ 0.06 Diluted earnings per Common Share: Income from continuing operations, net of tax $ 18,471 $ 4,300 Effect of assumed conversions: Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes 506 0 Income from continuing operations, net of tax after the effect of assumed conversions $ 18,977 $ 4,300 Income from discontinued operations, net of tax $ 4,386 $ 4,757 Weighted-average common shares outstanding 115,862 140,191 Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants 22,823 8,949 Weighted-average common shares outstanding assuming dilution 138,685 149,140 Diluted earnings from continuing operations per Common Share $ 0.14 $ 0.03 Diluted earnings from discontinued operations per Common Share 0.03 0.03 Net earnings per Common Share $ 0.17 $ 0.06
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following restricted stock unit awards, convertible notes and warrants are not included in the computation of diluted earnings per share as the effect of including such restricted stock unit awards, convertible notes and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2022 2021 Shares subject to anti-dilutive restricted stock unit awards, convertible notes and warrants excluded from calculation 0 5,360

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: March 31, 2022 December 31, 2021 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 254,385 $ ( 229,033 ) $ 25,352 $ 249,483 $ ( 227,408 ) $ 22,075 Customer contracts and relationships 404,934 ( 324,001 ) 80,933 397,445 ( 321,830 ) 75,615 Total $ 659,319 $ ( 553,034 ) $ 106,285 $ 646,928 $ ( 549,238 ) $ 97,690 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 520,187 506,607 Total $ 572,187 $ 558,607
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2022 were as follows: (In thousands) Veradigm Unallocated Total Balance as of December 31, 2021 467,630 38,977 506,607 Additions 13,580 0 13,580 Balance as of March 31, 2022 $ 481,210 $ 38,977 $ 520,187

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Instrument [Line Items]
Debt Outstanding Excluding Lease Obligations	Debt outstanding, excluding lease obligations, consists of the following: March 31, 2022 December 31, 2021 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 207,911 $ 4,331 $ 203,580 $ 167,853 $ ( 9,057 ) $ 176,910 Senior Secured Credit Facility 175,000 1,521 173,479 175,000 1,848 173,152 Total debt $ 382,911 $ 5,852 $ 377,059 $ 342,853 $ ( 7,209 ) $ 350,062 (1) As of March 31, 2022, the principal balance is recognized in debt. As of December 31, 2021, the principal balance is $ 207,911 thousand; $ 167,853 thousand is recognized in debt and $ 40,058 thousand is recognized in additional paid-in capital.
Interest Expense	Interest expense consists of the following: Three Months Ended March 31, (In thousands) 2022 2021 Interest expense $ 1,506 $ 1,288 Amortization of discounts and debt issuance costs 630 1,855 Total interest expense $ 2,136 $ 3,143
Summary of Future Debt Payment Obligations	Future Debt Payments The following table summarizes future debt principal payment obligations as of March 31, 2022: (In thousands) Total Remainder 2023 2024 2025 2026 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Revolving Facility (2) 175,000 0 175,000 0 0 0 0 Total debt $ 382,911 $ 0 $ 175,000 $ 0 $ 0 $ 0 $ 207,911 (1) Amount represents the face value of the 0.875 % Convertible Senior Notes. (2) Assumes no additional borrowings after March 31, 2022, payment of any required periodic installments of principal when due and that all drawn amounts are repaid upon maturity. On May 2, 2022, this amount was repaid with proceeds from the sale of the Hospitals and Large Physician Practices Business.
0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes	Interest expense related to the 0.875 % Convertible Senior Notes included in the table above consists of the following: Three Months Ended March 31, (In thousands) 2022 2021 Coupon interest $ 455 $ 455 Amortization of discounts and debt issuance costs 228 1,459 Total interest expense related to the convertible notes $ 683 $ 1,914

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Effective Tax Rates	The effective tax rates were as follows: Three Months Ended March 31, (In thousands, except effective tax rate) 2022 2021 Income from continuing operations before income taxes $ 4,050 $ 5,406 Income tax benefit (provision) $ 14,421 $ ( 1,106 ) Effective tax rate NM 20.5 % NM - We define “NM” as not meaningful for percentages greater than 200%.

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2022 Asset Derivatives (In thousands) Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 100 Total derivatives $ 100 December 31, 2021 Asset Derivatives (In thousands) Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 352 Total derivatives $ 352
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss): Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Location of Gain (Loss) Reclassified Three Months Foreign exchange contracts $ ( 148 ) Cost of Revenue $ 37 Selling, general and 24 Research and development $ 43 Amount of Gain (Loss) Recognized Amount of Gain (Loss) Reclassified from AOCI into Income (In thousands) Three Months Location of Gain (Loss) Reclassified Three Months Foreign exchange contracts $ 175 Cost of Revenue $ 321 Selling, general and 184 Research and development $ 351

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2021 (1) $ ( 3,026 ) $ 261 $ ( 2,765 ) Other comprehensive (loss) income before ( 150 ) ( 110 ) ( 260 ) Net losses (gains) reclassified from accumulated 0 ( 77 ) ( 77 ) Net other comprehensive income (loss) ( 150 ) ( 187 ) ( 337 ) Balance as of March 31, 2022 (2) $ ( 3,176 ) $ 74 $ ( 3,102 ) (1) Net of taxes of $91 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $25 thousand for unrealized net gains on foreign exchange contract derivatives. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2020 (1) $ ( 2,957 ) $ 1,119 $ ( 1,838 ) Other comprehensive income (loss) before 99 130 229 Net (gains) losses reclassified from accumulated 0 ( 635 ) ( 635 ) Net other comprehensive income (loss) 99 ( 505 ) ( 406 ) Balance as of March 31, 2021 (2) $ ( 2,858 ) $ 614 $ ( 2,244 ) (1) Net of taxes of $ 390 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $ 214 thousand for unrealized net gains on foreign exchange contract derivatives.
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2022 2021 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ ( 150 ) $ 0 $ ( 150 ) $ 99 $ 0 $ 99 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period ( 148 ) 38 ( 110 ) 175 ( 45 ) 130 Net (gains) losses reclassified into income ( 103 ) 26 ( 77 ) ( 856 ) 221 ( 635 ) Net change in unrealized gains (losses) on foreign exchange contracts ( 251 ) 64 ( 187 ) ( 681 ) 176 ( 505 ) Other comprehensive (loss) income $ ( 401 ) $ 64 $ ( 337 ) $ ( 582 ) $ 176 $ ( 406 )

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2022
Hospital And Large Physician Practices [Member]
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major classes of assets and liabilities of the Hospitals and Large Physician Practices Business as reported on the consolidated balance sheets as of March 31, 2022 and December 31, 2021: (In thousands) March 31, 2022 December 31, 2021 Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations: Cash and cash equivalents $ 67,671 $ 55,834 Restricted cash 847 861 Accounts receivable, net of allowance of $ 18,045 and $ 16,584 as of March 31, 2022 and December 31, 2021, respectively 200,407 155,447 Contract assets, net of allowance of $ 492 as of March 31, 2022 and December 31, 2021 68,786 61,382 Prepaid expenses and other current assets 63,310 58,431 Total current assets 401,021 331,955 Fixed assets, net 33,686 38,083 Software development costs, net 91,810 97,416 Intangible assets, net 77,997 86,240 Goodwill 467,725 467,871 Deferred taxes, net 8,393 6,607 Contract assets - long-term, net of allowance of $ 739 as of March 31, 2022 and December 31, 2021 31,934 28,623 Right-of-use assets - operating leases 48,089 50,585 Other assets 14,092 17,731 Total assets (1) $ 1,174,747 $ 1,125,111 Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations: Accounts payable $ 21,708 $ 11,555 Accrued expenses 45,852 38,007 Accrued compensation and benefits 37,506 61,167 Deferred revenue 274,541 205,152 Current operating lease liabilities 13,613 13,466 Total current liabilities 393,220 329,347 Deferred revenue long-term 475 2,568 Long-term operating lease liabilities 44,952 48,068 Other liabilities 341 270 Total liabilities (1) $ 438,988 $ 380,253 (1) The total assets and total liabilities in the above table for the three months ended March 31, 2022 and for the year ended December 31, 2021, are presented in the balance sheet as of March 31, 2022 as Assets held for sale and Liabilities related to assets held for sale. The following table summarizes the major income and expense line items of the Hospitals and Large Physician Practices Business as reported in the consolidated statements of operations for the three months ended March 31, 2022 and 2021. Three Months Ended March 31, (In thousands) 2022 2021 Major income and expense line items related to Hospitals and Large Physician Practices: Revenue: Provider $ 214,230 $ 234,700 Total revenue 214,230 234,700 Cost of revenue: Provider 143,692 147,572 Total cost of revenue 143,692 147,572 Gross profit 70,538 87,128 Selling, general and administrative expenses 48,749 49,545 Research and development 23,856 28,513 Amortization of intangible assets 3,450 3,460 (Loss) income from discontinued operations for Hospitals and Large Physician Practices ( 5,517 ) 5,610 Other income, net 496 239 (Loss) income from discontinued operations for Hospitals and Large Physician Practices before income taxes ( 5,021 ) 5,849 Income tax benefit (provision) 9,407 ( 1,556 ) Income from discontinued operations, net of tax for Hospitals and Large Physician Practices $ 4,386 $ 4,293
EPSi and CarePort [Member]
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statements of operations for the three months ended March 31, 2021. The activity during the three months ended March 31, 2021 relates to certain adjustments made in connection with the sale of EPSi and CarePort, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations. Three Months Ended (In thousands) March 31, 2021 Major income and expense line items related to EPSi and CarePort: Revenue: Provider $ ( 368 ) Total revenue ( 368 ) Cost of revenue: Provider ( 364 ) Total cost of revenue ( 364 ) Gross loss ( 4 ) Selling, general and administrative expenses 65 Research and development ( 40 ) Loss from discontinued operations for EPSi and CarePort ( 29 ) Gain on sale of discontinued operations 647 Income from discontinued operations for EPSi and CarePort before income taxes 618 Income tax provision ( 154 ) Income from discontinued operations, net of tax for EPSi and CarePort $ 464

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Our chief operating decision maker uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment. Three Months Ended March 31, (In thousands) 2022 2021 Revenue: Veradigm $ 136,278 $ 126,370 Unallocated Amounts 6,394 7,282 Total revenue $ 142,672 $ 133,652 Gross profit: Veradigm $ 69,195 $ 58,623 Unallocated Amounts 4,286 4,294 Total gross profit $ 73,481 $ 62,917 Income (loss) from operations: Veradigm $ 18,115 $ 11,494 Unallocated Amounts ( 11,543 ) ( 3,765 ) Total income (loss) from operations $ 6,572 $ 7,729

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	The majority of the restricted cash balance as of March 31, 2022 and 2021 represents lease deposits. March 31, (In thousands) 2022 2021 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 82,782 $ 453,772 Restricted cash 1,305 1,308 Total cash, cash equivalents and restricted cash $ 84,087 $ 455,080

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Basis Of Presentation And Significant Accounting Policies [Line Items]
Long-term Debt		$ 26,400
Additional paid-in capital		38,900
Retained earnings	$ 802,890	$ 12,500	$ 767,556
Accounting Standards Update 2020-06 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 1, 2022
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)Revenue_Stream	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams | Revenue_Stream	2
Total unsatisfied performance obligations	$ 1,000,000
Total unsatisfied performance obligations, percentage, year one	38.00%
Total unsatisfied performance obligations, percentage after year one	62.00%
Cumulative impact on retained earnings (accumulated deficit)	$ 1,353,106	$ 1,678,658	$ 1,408,138	$ 1,666,243
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	2,900	$ 3,300
Prepaid Expenses and Other Current Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	8,300		8,100
Other Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	$ 10,900		$ 11,900

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 36,151	$ 29,401
Revenue related to new performance obligations satisfied during the period	45,306	47,263
Revenue recognized under "right-to-invoice" expedient	61,114	56,811
Reimbursed travel expenses, shipping and other revenue	101	177
Total revenue	$ 142,672	$ 133,652

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Total revenue	$ 142,672	$ 133,652
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,394	7,282
Veradigm [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	136,278	126,370
Veradigm [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	136,278	126,370
Provider [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	118,665	111,170
Provider [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,394	7,282
Provider [Member] | Veradigm [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	112,271	103,888
Payer & Life Sciences
Disaggregation Of Revenue [Line Items]
Total revenue	24,007	22,482
Payer & Life Sciences | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	0	0
Payer & Life Sciences | Veradigm [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 24,007	$ 22,482

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Beginning Balance	$ 2,110	$ 2,110
Current period provision	0	0
Ending balance	2,110	2,110
Less: Contract assets, short-term	576	576	$ 576
Total contract assets, long-term	$ 1,534	$ 1,534	$ 1,534

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Trade Accounts Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss	$ 13,773	$ 13,360	$ 14,215	$ 14,769

Accounts Receivable - Schedule

Accounts Receivable - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Detail) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounts Notes And Loans Receivable [Line Items]
Beginning Balance	$ 13,360	$ 14,769
Current period provision	754	340
Write-offs	(341)	(894)
Ending Balance	$ 13,773	$ 14,215

Leases - Additional Information

Leases - Additional Information (Detail) - Maximum [Member]	3 Months Ended
	Mar. 31, 2022
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	5 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating C

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease cost	[1]	$ 1,690	$ 1,931
Less: Sublease income		(33)	(83)
Total operating lease costs		$ 1,657	$ 1,848
[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information for Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating cash flows from operating leases	$ 1,864	$ 1,506

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Right-of-use assets - operating leases	$ 16,776	$ 18,324
Current operating lease liabilities	5,972	6,133
Long-term operating lease liabilities	$ 15,241	$ 16,754
Weighted average remaining lease term (in years)	4 years	5 years
Weighted average discount rate	3.30%	3.40%

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Operating Leases [Abstract]
Operating Leases, Remainder of 2022	$ 4,945
Operating Leases, 2023	6,317
Operating Leases, 2024	3,602
Operating Leases, 2025	3,440
Operating Leases, 2026	2,835
Operating Leases, Thereafter	1,581
Operating Leases, Total lease liabilities	22,720
Operating Leases, Less: Amount representing interest	(1,507)
Operating Leases, Less: Short-term lease liabilities	(5,972)	$ (6,133)
Operating Leases, Total long-term lease liabilities	$ 15,241	$ 16,754

Business Combinations and Div_2

Business Combinations and Divestitures - Additional Information (Detail) - USD ($)	Mar. 25, 2022	Mar. 02, 2022	Aug. 23, 2021	Dec. 31, 2020	Oct. 29, 2020	Oct. 15, 2020	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Cash	$ 24,500,000
Purchase price in cash	24,100,000
Intangible assets	12,400,000
Goodwill	13,600,000						$ 520,187,000	$ 506,607,000
Deferred taxes, net	1,300						$ 0	16,625,000
2bPrecise [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business			$ 8,400,000
CarePort Purchase Agreement [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business								$ 600,000
CarePort Purchase Agreement [Member] | WellSky Corp [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business				$ 933,900,000
Sale of business unit				1,350,000,000
CarePort Purchase Agreement [Member] | WellSky Corp [Member] | Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt				$ 161,000,000
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business						$ 222,600,000
Sale of business unit						$ 365,000,000
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member] | Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt					$ 19,000,000
Babel Health [Member]
Business Acquisition [Line Items]
Total consideration for New Business	$ 24,000,000
Harris Dawn Holdings Inc. [Member]
Business Acquisition [Line Items]
Sale of business unit		$ 670,000,000
Additional cash		$ 30,000,000
American College of Cardiology [Member]
Business Acquisition [Line Items]
Date of acquisition							Mar. 25, 2022

Fair Value Measurements and L_3

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 56,191	$ 60,511
Total assets	100	352
Total liabilities	0	19
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	100	352
Total liabilities	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	19
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	100	352
Foreign exchange derivative assets [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Foreign exchange derivative assets [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	100	352
Foreign exchange derivative assets [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	19
Contingent Consideration Current [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	$ 0	$ 19

Fair Value Measurements and L_4

Fair Value Measurements and Long-term Investments - Summary of Changes in Liability Measured at Fair Value on Recurring Basis (Detail) - Contingent Consideration [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2021	$ 19
Payments	(19)
Balance at March 31, 2022	$ 0

Fair Value Measurements and L_5

Fair Value Measurements and Long-term Investments - Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		3 Months Ended
		Mar. 31, 2022USD ($)Investment	Dec. 31, 2021USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	4
Cost with adjustments, Number of investees | Investment		7
Total long-term equity investments, Number of Investees | Investment		11
Equity method investments, Original Cost	[1]	$ 7,099
Cost with adjustments, Original Cost		47,114
Total long-term equity investments, Original Cost		54,213
Equity method investments, Carrying Value	[1]	11,862	$ 12,260
Cost with adjustments, Carrying Value		48,791	49,293
Total long-term equity investments, Carrying Value		$ 60,653	$ 61,553
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and L_6

Fair Value Measurements and Long-term Investments - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment of long-term investments	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Jan. 24, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class Of Stock [Line Items]
Capitalized stock-based compensation costs		$ 0	$ 0
Stock options granted		0	0
Share issued, exercise of options and release of stock awards		1,000,000		2,200,000
Shares settled for tax withholding		628,000	383,000
Common stock repurchased, amount		$ 49,679,000	$ 0
Previous Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount		49,700,000	$ 0
Accelerated Share Repurchase Agreement [Member]
Class Of Stock [Line Items]
Shares of common stock yet to be repurchased, amount		$ 200,400,000
TwoThousandTwentyTwoStockPurchaseProgram
Class Of Stock [Line Items]
Common stock repurchased, shares		2,300,000
Common stock available to repurchase	$ 250,000,000

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 6,924	$ 3,954
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	305	333
Cost of revenue [Member] | Provider [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	317	276
Cost of revenue [Member] | Payer & Life Sciences
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	(12)	57
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	5,489	2,553
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,130	$ 1,068

Stockholders' Equity - Stock-_2

Stockholders' Equity - Stock-Based Awards Granted (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	25
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 19.86
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	25
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 19.86

Earnings (Loss) Per Share - Cal

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Basic earnings (loss) per Common Share:
Income from continuing operations	$ 18,471	$ 4,300
Income from discontinued operations, net of tax	4,386	4,757
Net income	$ 22,857	$ 9,057
Weighted-average common shares outstanding	115,862	140,191
Interest expense, net of tax, associated with 0.875% Convertible Senior Notes	$ 506	$ 0
Income from continuing operations, net of tax after the effect of assumed conversions	$ 18,977	$ 4,300
Continuing operations	$ 0.16	$ 0.03
Discontinued operations	0.04	0.03
Net income per share - Basic	$ 0.20	$ 0.06
Diluted earnings (loss) per Common Share:
Income from continuing operations, net of tax	$ 18,471	$ 4,300
Income from discontinued operations, net of tax	$ 4,386	$ 4,757
Weighted-average common shares outstanding	115,862	140,191
Plus: Dilutive effect of restricted stock unit awards and warrants	22,823	8,949
Weighted-average common shares outstanding assuming dilution	138,685	149,140
Diluted earnings (loss) from continuing operations per Common Share	$ 0.14	$ 0.03
Diluted earnings from discontinued operations per Common Share	0.03	0.03
Net income per share - Diluted	$ 0.17	$ 0.06

Earnings (Loss) Per Share - Ant

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Shares subject to anti-dilutive restricted stock unit awards and warrants excluded from calculation	0	5,360

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 25, 2022	Dec. 31, 2021
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 659,319		$ 646,928
Accumulated Amortization	(553,034)		(549,238)
Intangible Assets, Net	106,285		97,690
Registered trademarks	52,000		52,000
Goodwill	520,187	$ 13,600	506,607
Total	572,187		558,607
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	254,385		249,483
Accumulated Amortization	(229,033)		(227,408)
Intangible Assets, Net	25,352		22,075
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	404,934		397,445
Accumulated Amortization	(324,001)		(321,830)
Intangible Assets, Net	$ 80,933		$ 75,615

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Goodwill [Line Items]
Goodwill	$ 506,607
Additions	13,580
Goodwill	520,187
Veradigm [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill	467,630
Additions	13,580
Goodwill	481,210
Unallocated [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill	38,977
Additions	0
Goodwill	$ 38,977

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Debt - Debt Outstanding Excludi

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal Balance	$ 382,911	$ 342,853
Unamortized Discount and Debt Issuance Costs	5,852	(7,209)
Net Carrying Amount	377,059	350,062
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	207,911	167,853
Unamortized Discount and Debt Issuance Costs	4,331	(9,057)
Net Carrying Amount	203,580	176,910
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	175,000	175,000
Unamortized Discount and Debt Issuance Costs	1,521	1,848
Net Carrying Amount	$ 173,479	$ (173,152)

Debt - Debt Outstanding Exclu_2

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2019
Debt Instrument [Line Items]
Debt Instrument Carrying Amount	$ 382,911		$ 342,853
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,900		207,911	$ 218,000
Debt Instrument Carrying Amount	$ 207,911		167,853
Additional Paid-In Capital [Member] | 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument Convertible Carrying Amount Of The Equity Component		$ 40,100	$ 40,058	$ 40,100

Debt - Interest Expense (Detail

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Total interest expense	$ 2,136	$ 3,143
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	1,506	1,288
Amortization of discounts and debt issuance costs	630	1,855
Total interest expense	$ 2,136	$ 3,143

Debt - Interest Expense Related

Debt - Interest Expense Related to 0.875% Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Coupon interest	$ 455	$ 455
Amortization of discounts and debt issuance costs	228	1,459
Total interest expense related to the convertible notes	$ 683	$ 1,914

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2022	Jul. 20, 2020	Feb. 15, 2018	Jun. 30, 2020	Dec. 31, 2019	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument principal amount						$ 382,911	$ 342,853
Additional paid-in capital	$ 38,900
Long term debt	26,400
Retained Earnings Accumulated Deficit	12,500					802,890	767,556
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Senior secured credit facilities term, years			5 years
Credit facility, maximum borrowing capacity			$ 900,000
Fees and other costs, incurred		$ 1,400
Credit facility, amount available borrowing capacity						724,000
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						175,000	175,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						207,911	167,853
Debt instrument principal amount					$ 218,000	$ 207,900	207,911
Additional paid-in capital	38,900
Long term debt	26,400
Interest rate				0.875%	0.875%	0.875%
Debt issuance costs					$ 700
Percentage of interest rate used to to compute the initial fair value of the liability component					1.95%
Debt instrument, initial fair value of liability component					$ 177,900
Retained Earnings Accumulated Deficit	12,500
Debt instrument, net carrying value of equity component						$ 16,400
Payments for repurchase debt instrument				$ 7,700
Debt instrument aggregate principal amount repurchased				10,100
Gain on repurchase of debt instrument				500
Proceeds due to termination of capped call transaction				300
Reduction to capped call fees				800
Loss in capped call				$ 500
0.875% Convertible Senior Notes [Member] | Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument, equity component amount	40,100				40,100		$ 40,058
Payments of capped call fees					17,200
Debt discounts and issuance costs	$ 1,100				$ 1,100
Letter of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance			50,000
Swing Loans [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance			10,000
Foreign Currencies [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance			100,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity			$ 400,000
Line of credit facility, frequency of payments						We repaid the Term Loan in full on December 31, 2020.
Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						$ 175,000
Second Amended Credit Agreement [Member] | Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Letters of credit outstanding						$ 1,000
Second Amended Credit Agreement [Member] | Senior Secured Credit Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage						1.96%
Second Amended Credit Agreement [Member] | Senior Secured Credit Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread						1.50%

Debt - Summary of Future Debt P

Debt - Summary of Future Debt Payment Obligations (Detail) $ in Thousands	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
Total	$ 382,911
2022	0
2023	175,000
2024	0
2025	0
2026	0
Thereafter	207,911
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	207,911	[1]
2022	0	[1]
2023	0	[1]
2024	0	[1]
2025	0	[1]
2026	0	[1]
Thereafter	207,911	[1]
Revolving Facility [Member]
Debt Instrument [Line Items]
Total	175,000	[2]
2022	0	[2]
2023	175,000	[2]
2024	0	[2]
2025	0	[2]
2026	0	[2]
Thereafter	$ 0	[2]
[1]	Amount represents the face value of the 0.875 % Convertible Senior Notes.
[2]	Assumes no additional borrowings after March 31, 2022, payment of any required periodic installments of principal when due and that all drawn amounts are repaid upon maturity. On May 2, 2022, this amount was repaid with proceeds from the sale of the Hospitals and Large Physician Practices Business.

Debt - Summary of Future Debt_2

Debt - Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	Mar. 31, 2022	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate	0.875%	0.875%	0.875%

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income from continuing operations before income taxes	$ 4,050	$ 5,406
Income tax benefit (provision)	$ 14,421	$ (1,106)
Effective tax rate		20.50%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Windfall benefit	$ 5,100	$ 1,000
Income from continuing operations before income taxes	4,050	5,406
Pretax Income	$ 4,100	$ 5,400
Cumulative operating income loss period considered	3 years
Valuation allowance	$ 11,200
Unrecognized income tax benefits	30,500		$ 30,300
Deferred tax assets	7,000
Domestic Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance	$ 11,200

Derivative Financial Instrume_3

Derivative Financial Instruments - Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2020
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 100	$ 352
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 100	$ 352

Derivative Financial Instrume_4

Derivative Financial Instruments - Additional Information (Detail) - Foreign Exchange Forward Contracts [Member] ₨ in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022INR (₨)Number	Mar. 31, 2022USD ($)Number
Derivative [Line Items]
Number of contracts | Number	9	9
Foreign Currency Cash Flow Gain Loss To Be Reclassified During Specified Period | $		$ 0.1
Estimated period of unrealized losses included in AOCI reclassified into income	12 months
Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Dec. 31, 2022
Derivative notional amount outstanding	₨ 250	3.3
Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Apr. 30, 2022
Derivative notional amount outstanding	₨ 50	$ 0.7

Derivative Financial Instrume_5

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ 148	$ 175
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	37	321
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	24	184
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ 43	$ 351

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022		Mar. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ 1,408,138
Other comprehensive (loss) income before reclassifications	(260)		$ 229
Net losses (gains) reclassified from accumulated other comprehensive loss	(77)		(635)
Total other comprehensive income (loss)	(337)		(406)
Balance at the end of the period	1,353,106
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(3,026)	[1]	(2,957)	[2]
Other comprehensive (loss) income before reclassifications	(150)		(99)
Net losses (gains) reclassified from accumulated other comprehensive loss	0		0
Total other comprehensive income (loss)	(150)		99
Balance at the end of the period	(3,176)	[3]	(2,858)	[4]
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	261	[1]	1,119	[2]
Other comprehensive (loss) income before reclassifications	110		130
Net losses (gains) reclassified from accumulated other comprehensive loss	(77)		(635)
Total other comprehensive income (loss)	(187)		(505)
Balance at the end of the period	74	[3]	614	[4]
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(2,765)	[1]	(1,838)	[2]
Balance at the end of the period	$ (3,102)	[3]	$ (2,244)	[4]
[1]	Net of taxes of $91 thousand for unrealized net gains on foreign exchange contract derivatives.
[2]	Net of taxes of $ 390 thousand for unrealized net gains on foreign exchange contract derivatives.
[3]	Net of taxes of $25 thousand for unrealized net gains on foreign exchange contract derivatives.
[4]	Net of taxes of $ 214 thousand for unrealized net gains on foreign exchange contract derivatives.

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)		$ 214
Revaluation of tax effects	$ 390

Accumulated Other Comprehensi_5

Accumulated Other Comprehensive Loss - Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ (150)	$ 99
Foreign currency translation adjustments, Tax Effect	0	0
Foreign currency translation adjustments, Net	(150)	99
Other comprehensive (loss) income before income tax benefit	(401)	(582)
Other comprehensive income (loss), Tax effect	64	176
Total other comprehensive income (loss)	(337)	(406)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax, Amount	(148)	175
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	38	(45)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	(110)	130
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(103)	(856)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	26	221
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(77)	(635)
Derivatives qualifying as cash flow hedges, net change in unrealized gains (losses) on foreign exchange contracts, Before-Tax Amount, Total	(251)	(681)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	64	176
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent, Total	(187)	(505)
Total other comprehensive income (loss)	$ (187)	$ (505)

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - USD ($)	Apr. 05, 2022	Mar. 18, 2022	Dec. 31, 2020
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 200,000,000
Deferred Prosecution Agreement [Member]
Loss Contingencies [Line Items]
Increase (Decrease) in Other Deferred Liability		$ 200,000
Criminal Fine [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 25,300,000
Forfeiture Payment [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			959,700
Civil Settlements [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			118,600,000
State Medicaid Program Expenditures [Member] | US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 5,200,000

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2022SegmentBusiness
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of reportable segments | Segment	2
EPSi and CarePort [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of businesses sold | Business	2

Discontinued Operations - Summa

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands		Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents		$ 82,782	$ 132,517	$ 453,772
Total current assets		1,540,684	1,554,498
Total assets		2,430,255	2,425,229
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Total current liabilities		646,855	597,988
Total liabilities		1,077,149	1,017,091
Hospitals and Large Physician Practice [Member]
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents		67,671	55,834
Restricted Cash		847	861
Accounts receivable, net of allowance of $18,045 and $16,584 as of March 31, 2022 and December 31, 2021, respectively		200,407	155,447
Contract assets, net of allowance of [$0] as of March 31, 2022 and December 31, 2021		68,786	61,382
Prepaid expenses and other current assets		63,310	58,431
Total current assets		401,021	331,955
Fixed assets, net		33,686	38,083
Software development costs, net		91,810	97,416
Intangible assets, net		77,997	86,240
Goodwill		467,725	467,871
Deferred taxes, net		8,393	6,607
Contract assets - long-term, net of allowance of [$0] as of March 31, 2022 and December 31, 2021		31,934	28,623
Right-of-use assets - operating leases		48,089	50,585
Other assets		14,092	17,731
Total assets	[1]	1,174,747	1,125,111
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Accounts payable		21,708	11,555
Accrued expenses		45,852	38,007
Accrued compensation and benefits		37,506	61,167
Deferred revenue		274,541	205,152
Current operating lease liabilities		13,613	13,466
Total current liabilities		393,220	329,347
Deferred revenue long-term		475	2,568
Long-term operating lease liabilities		44,952	48,068
Other liabilities		341	270
Total liabilities	[1]	$ 438,988	$ 380,253
[1]	(1) The total assets and total liabilities in the above table for the three months ended March 31, 2022 and for the year ended December 31, 2021, are presented in the balance sheet as of March 31, 2022 as Assets held for sale and Liabilities related to assets held for sale.

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Parenthetical) (Detail) - Hospital And Large Physician Practices [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal group including discontinued operation accounts receivable, allowance	$ 18,045	$ 16,584
Disposal group including discontinued operation contract asset, allowance current	492	492
Disposal group including discontinued operation contract asset - long term, allowance	$ 739	$ 739

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Major Income and Expense Line Items Reported in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cost of revenue:
Gain on sale of discontinued operations	$ 0	$ 647
(Loss) Income from discontinued operations before income taxes	(5,021)	5,820
Income tax benefit (provision)	9,407	(1,710)
Income from discontinued operations, net of tax	4,386	4,757
Hospital And Large Physician Practices [Member]
Revenue:
Total revenue	214,230	234,700
Cost of revenue:
Total cost of revenue	143,692	147,572
Gross profit (loss)	70,538	87,128
Selling, general and administrative expenses	48,749	49,545
Research and development	23,856	28,513
Amortization of intangible assets	3,450	3,460
Income (loss) from discontinued operations	(5,517)	5,610
Other income, net	496	239
(Loss) Income from discontinued operations before income taxes	(5,021)	5,849
Income tax benefit (provision)	(9,407)	1,556
Income from discontinued operations, net of tax	4,386	4,293
EPSi and CarePort [Member]
Revenue:
Total revenue		(368)
Cost of revenue:
Total cost of revenue		(364)
Gross profit (loss)		(4)
Selling, general and administrative expenses		65
Research and development		(40)
Income (loss) from discontinued operations		(29)
Gain on sale of discontinued operations		647
(Loss) Income from discontinued operations before income taxes		618
Income tax benefit (provision)		154
Income from discontinued operations, net of tax		464
Provider [Member] | Hospital And Large Physician Practices [Member]
Revenue:
Total revenue	214,230	234,700
Cost of revenue:
Total cost of revenue	$ 143,692	147,572
Provider [Member] | EPSi and CarePort [Member]
Revenue:
Total revenue		(368)
Cost of revenue:
Total cost of revenue		$ (364)

Business Segments - Additional

Business Segments - Additional Information (Detail) - Segment	Jan. 01, 2022	Mar. 31, 2022
Segment Reporting [Abstract]
Number of operating segments	3,000
Number of reportable segments		2

Business Segments - Revenues an

Business Segments - Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 142,672	$ 133,652
Gross profit	73,481	62,917
Income (loss) from operations	6,572	7,729
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	6,394	7,282
Gross profit	4,286	4,294
Income (loss) from operations	11,543	(3,765)
Veradigm [Member]
Segment Reporting Information [Line Items]
Revenue	136,278	126,370
Gross profit	69,195	58,623
Income (loss) from operations	$ 18,115	$ 11,494

Supplemental Disclosures - Supp

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 82,782	$ 132,517	$ 453,772
Restricted cash	1,305	$ 1,308	1,308
Total cash, cash equivalents and restricted cash	$ 84,087		$ 455,080

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Mar. 02, 2022	Apr. 29, 2022
H L P P Divestiture [Member]
Subsequent Event [Line Items]
Sale of business unit	$ 670
Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Borrowing Capacity		$ 700
Available for the issuance of letters of credit		50
Available for swingline loans		25
Credit facility borrowed under certain foreign currencies		$ 100
Maximum [Member] | Hospitals and Large Physician Practices Business [Member]
Subsequent Event [Line Items]
Additional cash	$ 30